Penicillin-G-benzathine
Phase 3Small molecule
PfizerPenicillin-G-benzathine is one of 35 small molecule programs targeting Syphilis. It is currently in Phase 3.
2
Indications
5
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Pharyngitis
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Bayer Aspirin
BayerApproved
Biaxin
AbbVieApproved
Ketek
SanofiApproved
Anjeso
Boehringer IngelheimApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Advil
KKenvue Brands
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pharyngitis1 trial
Syphilis1 trial
Oral Amoxicillin Compared to Penicillin G Benzathine for the Treatment of Acquired Syphilis.
Active, not recruiting·—·Phase 3·NCT06877351·120 enrolled
Trial1 trial
A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)
Completed·—··NCT05211024·1,423 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Penicillin-G-benzathine. EMBL-EBI & Wellcome Sanger Institute.
- [4]